BBOT
BridgeBio·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BBOT
Bridgebio Oncology Therapeutics, Inc.
A clinical-stage biopharmaceutical company headquartered in South San Francisco,California,USA
256 E. Grand Avenue, Suite 104, South San Francisco, CA 94080
Develops small molecule therapeutics targeting RAS and PI3K malignancies.
BridgeBio Oncology Therapeutics, Inc., was incorporated as a Cayman Islands exempted company on June 15, 2021. Effective August 12, 2025, the Company completed the previously announced Business Combination, with the combined company's place of incorporation in Delaware. BBOT is a clinical-stage biotechnology company whose mission is to transform the lives of cancer patients driven by the two most commonly mutated oncogenes, RAS and PI3Kα.
Company Financials
EPS
BBOT has released its 2026 Q2 earnings. EPS was reported at -0.71, versus the expected -0.57, missing expectations. The chart below visualizes how BBOT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
